公开(公告)号：US20090269850A1

公开(公告)日：2009-10-29

申请号：US12085355

申请日：2006-11-24

申请人： Yasufumi Kaneda ,  Katsuto Tamai ,  Kotaro Saga ,  Masako Kawachi

发明人： Yasufumi Kaneda ,  Katsuto Tamai ,  Kotaro Saga ,  Masako Kawachi

IPC分类号： C12N15/86 ,  C12N7/01 ,  C12N5/10 ,  C07K14/00 ,  C07K16/00 ,  C07H21/02 ,  C07H21/04

CPC分类号： C12N7/00 ,  C07K14/005 ,  C07K2319/30 ,  C07K2319/33 ,  C12N15/1131 ,  C12N15/86 ,  C12N2310/14 ,  C12N2760/18821 ,  C12N2760/18822 ,  C12N2760/18843 ,  C12N2760/18845 ,  C12N2810/859

摘要： The present invention provides a modified paramyxovirus containing a reduced amount of receptor-binding protein compared with the wild type; a method of preparing a modified paramyxovirus, comprising the following steps: (1) a step for introducing a nucleic acid that suppresses the expression of a receptor-binding protein of a paramyxovirus into an animal cell, (2) a step for infecting the paramyxovirus to the cell, and (3) a step for isolating paramyxovirus particles replicated in the cell; and a modified paramyxovirus prepared by the method of preparation mentioned above.The present invention also provides a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker; a nucleic acid that encodes the chimera protein; an animal cell capable of expressing the chimera protein on the cell surface thereof; a modified paramyxovirus expressing the chimera protein on the virus particle surface thereof; and a method of preparing a tissue targeting paramyxovirus, comprising: (1) a step for supplying a nucleic acid that encodes a chimera protein wherein a fusion protein of a virus has been joined or bound to a peptide that binds specifically to a cell surface marker of the target cells, (2) a step for introducing the nucleic acid supplied in (1) into an animal cell in an expressible state, and expressing the same, (3) a step for infecting a paramyxovirus to the cell, and (4) a step for isolating paramyxovirus particles replicated in the cell.

摘要翻译： 本发明提供了与野生型相比含有减少量的受体结合蛋白的修饰的副粘病毒; 一种制备修饰的副粘病毒的方法，包括以下步骤：（1）将抑制副粘病毒的受体结合蛋白的表达的核酸引入动物细胞的步骤，（2）感染副粘病毒的步骤 （3）用于分离复制在细胞中的副粘病毒颗粒的步骤; 和通过上述制备方法制备的修饰的副粘病毒。 本发明还提供一种嵌合体蛋白，其中病毒的融合蛋白已经与特异性结合于细胞表面标记的肽结合或结合; 编码嵌合蛋白的核酸; 能够在其细胞表面上表达嵌合体蛋白质的动物细胞; 在病毒颗粒表面上表达嵌合体蛋白质的修饰的副粘病毒; 以及制备组织靶向副粘病毒的方法，包括：（1）提供编码嵌合体蛋白的核酸的步骤，其中病毒的融合蛋白已经结合或与特异性结合于细胞表面标记的肽结合 的靶细胞，（2）将（1）中提供的核酸以可表达状态引入动物细胞中并表达其的步骤，（3）感染细胞的副粘病毒的步骤，（4 ）分离在细胞中复制的副粘病毒颗粒的步骤。

公开(公告)号：US20090224854A1

公开(公告)日：2009-09-10

申请号：US12397719

申请日：2009-03-04

申请人： Kouta OHKUBO ,  Yasufumi Kaneda

发明人： Kouta OHKUBO ,  Yasufumi Kaneda

IPC分类号： H03H9/00

CPC分类号： H03H9/02637 ,  H03H9/0057 ,  H03H9/6473 ,  H03H9/6476

摘要： An acoustic wave filter includes a piezoelectric substrate, an IDT (interdigital transducer) formed on the piezoelectric substrate, and reflectors located at both sides of the IDT and composed of electrode fingers, at least one of the electrode fingers of at least one of the reflectors including at least one gap within a propagation path of an acoustic wave.

摘要翻译： 声波滤波器包括压电基片，形成在压电基片上的IDT（叉指式换能器）和位于IDT两侧并由电极指构成的反射器，至少一个反射器的电极指中的至少一个 包括在声波的传播路径内的至少一个间隙。

公开(公告)号：US20070287677A1

公开(公告)日：2007-12-13

申请号：US10594659

申请日：2005-03-30

申请人： Yasufumi Kaneda

发明人： Yasufumi Kaneda

IPC分类号： A61K31/70 ,  A61K31/28 ,  A61P43/00 ,  C07D239/42 ,  C07H21/04 ,  C12N15/00 ,  C12N5/08

CPC分类号： A61K31/282 ,  A61K31/7088 ,  A61K33/24 ,  A61K45/06 ,  C12N15/113 ,  C12N2310/14 ,  A61K2300/00

摘要： A double stranded RNA having a specific nucleotide sequence is useful for treating cellular proliferative disorders. The double stranded RNA acts as siRNA against the Rad51 gene. The double stranded RNA of the present invention inhibits cellular proliferation itself. In addition, co-administration of the double stranded RNA with a chemotherapeutic agent further enhances its pharmacological effect. The combined use of the double stranded RNA with an agent having a nucleic acid synthesis-inhibitory activity or a nucleic acid-impairing activity is particularly effective.

摘要翻译： 具有特异性核苷酸序列的双链RNA可用于治疗细胞增殖性疾病。 双链RNA作为针对Rad51基因的siRNA。 本发明的双链RNA本身抑制细胞增殖。 此外，双链RNA与化学治疗剂的共同给药进一步增强其药理作用。 双链RNA与具有核酸合成抑制活性或核酸损害活性的试剂的组合使用是特别有效的。

公开(公告)号：US20070281888A1

公开(公告)日：2007-12-06

申请号：US10593518

申请日：2005-03-17

申请人： Tomoyuki Nishikawa ,  Hironori Nakagami ,  Yasufumi Kaneda

发明人： Tomoyuki Nishikawa ,  Hironori Nakagami ,  Yasufumi Kaneda

IPC分类号： A61K38/18 ,  A61K31/7052 ,  A61P43/00 ,  A61P5/00 ,  C07H21/00 ,  C07K14/00 ,  C12N15/00 ,  C12N15/63 ,  C12N15/87 ,  C12N5/08

CPC分类号： C12N15/86 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  C07K14/515 ,  C07K14/52 ,  C12N2760/18643 ,  C12N2760/18671

摘要： It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and/or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and/or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.

摘要翻译： 旨在提供具有生长血管内皮细胞活性的新型多肽，促进c-fos启动子转录的活性，促进VEGF启动子的转录活性和/或血管生成活性的活性; 编码该多肽的多核苷酸; 上述多肽和/或含有治疗选自以下的疾病多肽的药物组合物：阻塞性动脉硬化，Buerger氏病，外周血管病症，心绞痛，心肌梗死，脑梗塞，缺血性心脏病和缺血性脑病; 一种治疗这些疾病的方法; 和抗菌组合物。 通过分离具有上述活性的新肽和编码该肽的核苷酸可以解决上述问题。

公开(公告)号：US07291904B2

公开(公告)日：2007-11-06

申请号：US11115253

申请日：2005-04-27

申请人： Takashi Matsuda ,  Suguru Warashina ,  Masanori Ueda ,  Osamu Kawachi ,  Yasufumi Kaneda

发明人： Takashi Matsuda ,  Suguru Warashina ,  Masanori Ueda ,  Osamu Kawachi ,  Yasufumi Kaneda

IPC分类号： H01L23/02 ,  H01L23/06 ,  H01L23/48 ,  H01L23/52 ,  H03H9/10

CPC分类号： H03H9/1071 ,  H01L2224/05568 ,  H01L2224/05573 ,  H01L2224/16225 ,  H01L2924/00014 ,  H01L2924/15174 ,  H01L2924/15184 ,  H03H9/0071 ,  H03H9/059 ,  H03H9/1078 ,  H01L2224/05599

摘要： A package substrate includes signal pads provided on a main surface of the package substrate, footpads provided on a backside of the package substrate, and a sealing electrode provided on the main surface to surround the signal pads, the signal pads being electrically coupled to the footpads, the sealing electrode being insulated from the footpads.

摘要翻译： 封装衬底包括设置在封装衬底的主表面上的信号焊盘，设置在封装衬底的背面上的脚垫和设置在主表面上以围绕信号焊盘的密封电极，信号焊盘电耦合到脚垫 密封电极与脚垫绝缘。

公开(公告)号：US20050239188A1

公开(公告)日：2005-10-27

申请号：US11126770

申请日：2005-05-10

申请人： Yasufumi Kaneda

发明人： Yasufumi Kaneda

IPC分类号： A61K48/00 ,  C12N7/04 ,  C12N15/87 ,  C12N15/88 ,  C12N15/86 ,  C12N7/00

CPC分类号： C12N7/00 ,  A61K48/00 ,  C12N15/87 ,  C12N15/88 ,  C12N2710/16663 ,  C12N2760/18823 ,  C12N2760/18861 ,  C12N2760/18863

摘要： A gene transfer vector is prepared by introducing an exogenous gene into an inactivated virus envelope, through a freezing and thawing treatment or mixing with a detergent. There are also provided a pharmaceutical composition for gene therapy containing this gene transfer vector, a kit containing this gene transfer vector, and a gene transfer method employing this gene transfer vector.

摘要翻译： 通过冷冻和解冻处理或与洗涤剂混合将外源基因导入灭活的病毒包膜中制备基因转移载体。 还提供了含有该基因转移载体的基因治疗药物组合物，含该基因转移载体的试剂盒和使用该基因转移载体的基因转移方法。

公开(公告)号：US06913923B2

公开(公告)日：2005-07-05

申请号：US09937839

申请日：2001-02-02

申请人： Yasufumi Kaneda

发明人： Yasufumi Kaneda

IPC分类号： A61K48/00 ,  C12N7/04 ,  C12N15/87 ,  C12N15/88 ,  C12N15/00 ,  C12N15/09 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74

CPC分类号： C12N7/00 ,  A61K48/00 ,  C12N15/87 ,  C12N15/88 ,  C12N2710/16663 ,  C12N2760/18823 ,  C12N2760/18861 ,  C12N2760/18863

摘要： A gene transfer vector is prepared by introducing an exogenous gene into an inactivated virus envelope, through a freezing and thawing treatment or mixing with a detergent. There are also provided a pharmaceutical composition for gene therapy containing this gene transfer vector, a kit containing this gene transfer vector, and a gene transfer method employing this gene transfer vector.

公开(公告)号：US20120251510A1

公开(公告)日：2012-10-04

申请号：US13503329

申请日：2010-10-28

申请人： Katsuto Tamai ,  Yasufumi Kaneda ,  Takehiko Yamazaki ,  Takenao Chino ,  Kotaro Saga ,  Mayumi Endo

发明人： Katsuto Tamai ,  Yasufumi Kaneda ,  Takehiko Yamazaki ,  Takenao Chino ,  Kotaro Saga ,  Mayumi Endo

IPC分类号： A61K38/17 ,  C12N5/10 ,  C12N15/85 ,  C12N5/0775 ,  A61K31/7088 ,  A61P25/00 ,  A61P19/00 ,  A61P17/00 ,  C07K14/47 ,  A61K35/12

CPC分类号： A61K35/28 ,  A61K48/00 ,  C07K14/47

摘要： It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

摘要翻译： 据透露，HMGB-1和S100A8的静脉内给药通过将骨髓来源的细胞募集到皮肤溃疡部位来促进皮肤溃疡愈合。 此外，在脑梗死后，将HMGB-1静脉内施用于脑梗死模型小鼠时，在脑中检测到表达神经细胞标志物的骨髓来源的细胞。 与对照相比，静脉内施用HMGB-1的小鼠中观察到显着的脑梗死减轻作用。 静脉注射HMGB-1给药组脑梗死后存活率升高。 使用小鼠评估骨髓多能干细胞参与骨折愈合过程，结果表明远离受损部位的骨髓来源的细胞迁移到骨折部位以修复受损组织。

公开(公告)号：US08093101B2

公开(公告)日：2012-01-10

申请号：US11598816

申请日：2006-11-14

申请人： Kaoru Sakinada ,  Takumi Kooriike ,  Shunichi Aikawa ,  Osamu Kawachi ,  Yasufumi Kaneda

发明人： Kaoru Sakinada ,  Takumi Kooriike ,  Shunichi Aikawa ,  Osamu Kawachi ,  Yasufumi Kaneda

IPC分类号： H01L21/00

CPC分类号： B23K1/0016 ,  H01L23/10 ,  H01L24/97 ,  H01L2224/0554 ,  H01L2224/05568 ,  H01L2224/05573 ,  H01L2224/16225 ,  H01L2224/73253 ,  H01L2224/97 ,  H01L2924/00014 ,  H01L2924/01079 ,  H03H9/059 ,  H03H9/1078 ,  H03H9/1085 ,  H01L2224/81 ,  H01L2224/05599 ,  H01L2224/0555 ,  H01L2224/0556

摘要： There is provided a method of fabricating an electronic device including flip-chip mounting a device chip on a substrate, and supplying solder between adjacent device chips by supplying the solder on the device chips and applying heat and pressure on the solder, and a contact angle of the device chip and the solder is greater than 90° with the solder melted.

摘要翻译： 提供了一种制造电子器件的方法，该电子器件包括将器件芯片安装在衬底上的倒装芯片，以及通过在器件芯片上提供焊料并在焊料上施加热和压力来在相邻器件芯片之间提供焊料，以及接触角 的焊料熔化时，器件芯片和焊料大于90°。

公开(公告)号：US20110268769A1

公开(公告)日：2011-11-03

申请号：US13103275

申请日：2011-05-09

申请人： Yasufumi Kaneda ,  Chun-Man Lee ,  Yasuhiko Tabata ,  Tomoyuki Asano

发明人： Yasufumi Kaneda ,  Chun-Man Lee ,  Yasuhiko Tabata ,  Tomoyuki Asano

IPC分类号： A61K9/00 ,  A61K31/69 ,  A61K38/00 ,  A61P35/00 ,  A61K47/36 ,  A61K31/7088

CPC分类号： A61K31/69 ,  A61K31/7088 ,  A61K47/60 ,  A61K47/61 ,  A61K48/0008 ,  C12N7/00 ,  C12N2760/18842 ,  C12N2760/18851 ,  C12N2760/18862 ,  C12N2760/18863

摘要： The invention provides a vehicle that can deliver drugs specifically to the body and a pharmaceutical preparation using the same. Disclosed is a drug delivery vehicle for cancer therapy, comprising a cationized viral envelope vector, as well as a pharmaceutical preparation comprising a drug enclosed in the vehicle. The viral envelope vector is for example HVJ-E derived from a Sendai virus, and cationization can be conducted by binding hyaluronic acid-introduced cationized gelatin or ethylene glycol-introduced cationized gelatin with the viral envelope vector. The drug to be enclosed is a nucleic acid, a vector containing a nucleic acid sequence, a protein based drug or pharmaceutical with a low-molecular compound.

摘要翻译： 本发明提供了能够将药物特异性地递送到身体的载体和使用其的药物制剂。 公开了一种用于癌症治疗的药物递送载体，其包含阳离子化病毒包膜载体，以及包含在载体中的药物的药物制剂。 病毒包膜载体是例如源自仙台病毒的HVJ-E，阳离子化可以通过将透明质酸引入的阳离子化明胶或乙二醇引入的阳离子化明胶与病毒包膜载体结合来进行。 待封闭的药物是核酸，含有核酸序列，基于蛋白质的药物或具有低分子化合物的药物的载体。